Breast and axillary marking in the neoadjuvant setting: survey results from experts of the Brazilian society of mastology
Year: 2024
Type: article
Study design: Observational Study
Abstract: Introduction/objectives The precise location of the tumor site is essential for the success of surgical treatment. Neoadjuvant chemotherapy (NAC) is a challenge for preoperative tumor and node localization. Thus, the knowledge and attitudes of the affiliated members of the Brazilian Society of Mastology (SBM) regarding breast and axilla marking were evaluated and a consensus regarding management and treatment was reached. Methods This was an online survey conducted between June and December 2022. All 1,742 active mastologists affiliated to the SBM were invited anonymously. The online form contained 28 objective questions, of which 22 were formulated on a Likert scale. These questions addressed relevant aspects related to breast and axilla marking in the neoadjuvant setting. Responses that reached 70% agreement were considered consensual. Statistical analysis was performed using the SPSS program version 26.0. Post hoc analysis was performed when appropriate and the significance level was set at p < 0.05. Polychoric regression analyses were conducted using `VGAM` package Results In total, 468 mastologists answered the questionnaire (26.8%), with a predominance of professionals aged between 40–49 years (32.1%). Most professionals were board-certified (84,8%). The indication of tumor marking in the breast prior to NAC was consensual (96.4%) and the metal clip was the preferred method (69.7%). There was no consensus regarding the indication of pre-NAC histologically positive lymph node marking (49.8% disagree and 42.8% agree). However, there was consensus that the clinical and imaging evaluation was insufficient for staging the axilla as N1 (71.6%). The contraindication of breast and node marking in T4b tumors (71.2%) was consensual. There was consensus on the indication of sentinel lymph node biopsy (SLNB) for initially cN1 (92.3%) or cN2 (72.7%) tumors that became cN0 after NAC, with 67.5% opting for dual staining with technetium and patent blue. When <3 lymph nodes were retrieved 41.0% of mastologists performed axillary lymphadenectomy. Among the 28 questions, consensus was reached on only 11 (39.3%). Conclusion The indication of pre-NAC breast marking is consensual among Brazilian mastologists, although axillary nodal marking is not. There is a great divergence of attitudes among Brazilian surgeons in relation to the many issues related to pre-NAC breast and axilla marking.
Source: Frontiers in Oncology
Authors: Henrique Lima Couto, Augusto Tufi Hassan, Dalton Ivan Steinmacher, Eduardo Carvalho Pessoa, Eduardo Camargo Millen, Felipe Zerwes, Francisco Pimentel Cavalcante, Giuliano Tosello, Guilherme Novita, Gustavo Machado Badan, José Luis Esteves Francisco, Leonardo Ribeiro Soares, Lucas Roskamp Budel, Luciano Fernandes Chala, Raquel Civolani Marques Fernandes, Ruffo Freitas-Junior, Vilmar Marques de Oliveira, Vinicius Milani Budel, André Mattar
Institutions: Centro Universitário Cesumar, Universidade Estadual Paulista (Unesp), Pontifícia Universidade Católica do Rio Grande do Sul, Hospital Geral de Fortaleza, Faculdade de Medicina de São José do Rio Preto, Universidade Federal de Goiás, Universidade Federal do Paraná, Fleury S.A. (Brazil), Hospital da Mulher São Paulo, Centro de Referência da Saúde da Mulher - Hospital da Mulher São Paulo
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,295
OpenAlex ID: W4403268564
